Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Price, News & Analysis

Company Overview

Harrow Health, Inc. is a diversified biopharmaceutical company focused on improving patient access to innovative ophthalmic therapies. Through its wholly owned subsidiary ImprimisRx®, Harrow Health develops, manufactures and distributes proprietary compounded and generic eye drop formulations for treating a range of anterior segment eye diseases. The company’s product portfolio addresses conditions such as glaucoma, ocular pain and inflammation, and dry eye, and it leverages a direct‐to‐physician distribution model alongside select pharmacy and specialty pharmacy partnerships.

Since its founding, Harrow Health has expanded beyond traditional compounding to pursue the commercialization of branded pharmaceutical candidates and digital therapeutics. These efforts include licensing agreements for novel small‐molecule ocular drugs and the development of proprietary platforms aimed at improving formulation stability and patient compliance. Harrow Health’s business strategy emphasizes rapid commercialization of off‐patent ophthalmic formulations while building a pipeline of differentiated products for long‐term growth.

Headquartered in Tampa, Florida, Harrow Health serves healthcare providers and patients across the United States, with additional international reach through a network of third-party distributors. The company’s leadership team combines experience in pharmaceutical development, regulatory affairs and specialty pharmacy operations, under the guidance of Chief Executive Officer Anthony Johnson. In April 2022, Harrow Health issued its 11.875% Senior Notes due 2027 (NASDAQ: HROWM) to support ongoing research and development, marketing initiatives and potential strategic acquisitions within the ophthalmology sector.

Key Stats

• Today's Range: $26.03 to $26.03
• 50-Day Range: $25.94 to $26.35
• 52-Week Range: $25.80 to $26.95
• Volume: N/A
• Average Volume: 7,506 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HROWM
• CIK: 1360214
• Web: harrowinc.com
• Phone: N/A
• Fax: N/A
• Employees: 125
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A